AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims in the application.

Listing of Claims:

1. (Currently Amended) A pharmaceutical dosage form suitable for intravenous injection comprising:

(a) a liquid dispersion medium;

(b) particles of meloxicam or a salt thereof having an effective average particle size of less than ~~2000~~ 200 nm; and

(c) polyvinylpyrrolidone, sodium deoxycholate, or a combination of polyvinylpyrrolidone and sodium deoxycholate as a surface stabilizer adsorbed on the surface of the meloxicam particles,

wherein:

(i) the surface stabilizer is essentially free of intermolecular cross-linkages;

(ii) meloxicam is present in an amount of from about 99.5% to about 0.001%, by weight, based on the total combined weight of the meloxicam and at least one surface stabilizer; and

(iii) the surface stabilizer is present in an amount of from about 0.01% to about 99.5%, by weight, based on the total combined weight of the meloxicam and at least one surface stabilizer.

2. (Previously Presented) The pharmaceutical dosage form of claim 1, wherein the meloxicam is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

3. (Currently Amended) The pharmaceutical dosage form of claim 1, wherein the effective average particle size of the meloxicam particles is selected from the group consisting of ~~less than 1500 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less~~

~~than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm,~~ less than 100 nm, less than 75 nm, and less than 50 nm.

4.-5. (Cancelled)

6. (Previously Presented) The pharmaceutical dosage form of claim 1, wherein the pharmaceutical dosage form further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

7.-25. (Cancelled)

26. (Withdrawn-Currently Amended) A method of making a ~~nanoparticulate composition~~ pharmaceutical dosage form suitable for intravenous injection comprising contacting meloxicam particles with ~~at least one surface stabilizer selected from the group consisting of~~ polyvinylpyrrolidone, sodium deoxycholate, [[and]] or a combination of polyvinylpyrrolidone and sodium deoxycholate as surface stabilizers in the presence of a liquid dispersion medium for a time and under conditions sufficient to provide ~~a nanoparticulate meloxicam composition~~ the pharmaceutical dosage form comprising meloxicam particles having an effective average particle size of less than ~~2000~~ 200 nm,

wherein:

(i) the surface stabilizer is essentially free of intermolecular cross-linkages;

(ii) meloxicam is present in an amount of from about 99.5% to about 0.001, by weight, based on the total combined weight of the meloxicam and at least one surface stabilizer; and

(iii) the surface stabilizer is present in an amount of from about 0.01% to about 99.5%, by weight, based on the total combined dry weight of meloxicam and at least one surface stabilizer.

~~, and wherein in comparative pharmacokinetic testing with a non-nanoparticulate formulation of meloxicam having the same dosage strength and form, the nanoparticulate~~

~~composition exhibits a shorter time to T_{max} when compared to the time to T_{max} of the non-nanoparticulate meloxicam formulation~~.

27. (Withdrawn) The method of claim 26, wherein said contacting comprises grinding.

28. (Withdrawn) The method of claim 27, wherein said grinding comprises wet grinding.

29. (Withdrawn) The method of claim 26, wherein said contacting comprises homogenizing.

30. (Withdrawn) The method of claim 26, wherein said contacting comprises:

(a) dissolving the meloxicam particles in a solvent;

(b) adding the resulting meloxicam solution to a solution comprising at least one surface stabilizer; and

(c) precipitating the solubilized meloxicam having at least one surface stabilizer associated with the surface thereof by the addition thereto of a non-solvent.

31. (Withdrawn) The method of claim 26, wherein the meloxicam is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

32. (Withdrawn-Currently Amended) The method of claim 26, wherein the effective average particle size of the nanoparticulate meloxicam particles is selected from the group consisting of ~~less than 1500 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm,~~ less than 100 nm, less than 75 nm, and less than 50 nm.

33.-34. (Cancelled)

35. (Withdrawn – Currently Amended) The method of claim 26, wherein the ~~composition~~ pharmaceutical dosage form further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

36.-49. (Cancelled)

50. (Currently Amended) A method of treating a subject in need comprising intravenously injecting to the subject an effective amount of a pharmaceutical dosage form comprising:

(a) a liquid dispersion medium;

(b) particles of meloxicam or a salt thereof; and

(c) polyvinylpyrrolidone, sodium deoxycholate, or a combination of polyvinylpyrrolidone and sodium deoxycholate as surface stabilizers,

wherein:

(i) the surface stabilizer is essentially free of intermolecular cross-linkages;~~, and wherein~~

(ii) the meloxicam particles have an effective average particle size of less than ~~2000~~ 200 nm;

(iii) meloxicam is present in an amount of from about 99.5% to about 0.001, by weight, based on the total combined weight of the meloxicam and at least one surface stabilizer; and

(iv) the surface stabilizer is present in an amount of from about 0.01% to about 99.5%, by weight, based on the total combined dry weight of meloxicam and at least one surface stabilizer.

51. (Previously Presented) The method of claim 50, wherein the meloxicam is selected from the group consisting of a crystalline phase, an amorphous phase, and a semi-crystalline phase.

52. (Currently Amended) The method of claim 50, wherein the effective average particle size of the nanoparticulate meloxicam particles is selected from the group consisting of ~~less than 1500 nm, less than 1000 nm, less than 900 nm, less than 800 nm, less than 700 nm, less than 600 nm, less than 500 nm, less than 400 nm, less than 300 nm, less than 250 nm, less than 200 nm,~~ less than 100 nm, less than 75 nm, and less than 50 nm.

53.-54. (Cancelled)

55. (Previously Presented) The method of claim 50, wherein the pharmaceutical dosage form further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.

56.-64. (Cancelled)

65. (Previously Presented) The method of claim 50, wherein the method is used to treat a condition selected from the group consisting of conditions in which NSAIDs are contraindicated, arthritic disorders, gastrointestinal conditions, inflammatory conditions, pulmonary inflammation, opthalmic diseases, central nervous systems disorders, pain, fever, inflammation-related cardiovascular disorders, angiogenesis-related disorders, benign tumors, malignant tumors, adenomatous polyps, endometriosis, osteoporosis, dysmenorrhea, premature labor, asthma, fibrosis which occurs with radiation treatment, eosinophil-related disorders, pyrexia, bone resorption, nephrotoxicity, hypotension, arthrosis, joint stiffness, kidney disease, liver disease, acute mastitis, diarrhea, colonic adenomas, bronchitis, allergic neuritis, cytomegalovirus infectivity, apoptosis, lumbago, psoriasis, eczema, acne, burns, dermatitis, ultraviolet radiation damage, allergic rhinitis, respiratory distress syndrome, and endotoxin shock syndrome.

66. (Previously Presented) The method of claim 50 , wherein the method is used to treat an indication in which anti-inflammatory agents, anti-angiogenesis agents, antitumorigenic

agents, immunosuppressive agents, NSAIDs, COX-2 inhibitors, analgesic agents, anti-thrombotic agents, narcotics, or antifebrile agents are typically used.

67. (Previously Presented) The method of claim 50, wherein said subject is a human.

68.-100. (Cancelled)

101. (Previously Presented) The pharmaceutical dosage form of claim 1, wherein the pharmaceutical dosage form comprises polyvinylpyrrolidone as the surface stabilizer.

102. (Previously Presented) The pharmaceutical dosage form of claim 1, wherein the pharmaceutical dosage form comprises sodium deoxycholate as the surface stabilizer.

103. (Previously Presented) The pharmaceutical dosage form of claim 1, wherein the pharmaceutical dosage form comprises polyvinylpyrrolidone and sodium deoxycholate as the surface stabilizers.

104.-105. (Cancelled)